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ABSTRACT
Objectives Non- contrast CT aortic valve calcium 
scoring ignores the contribution of valvular fibrosis in 
aortic stenosis. We assessed aortic valve calcific and non- 
calcific disease using contrast- enhanced CT.
Methods This was a post hoc analysis of 164 patients 
(median age 71 (IQR 66–77) years, 78% male) with 
aortic stenosis (41 mild, 89 moderate, 34 severe; 
7% bicuspid) who underwent echocardiography and 
contrast- enhanced CT as part of imaging studies. 
Calcific and non- calcific (fibrosis) valve tissue volumes 
were quantified and indexed to annulus area, using 
Hounsfield unit thresholds calibrated against blood 
pool radiodensity. The fibrocalcific ratio assessed the 
relative contributions of valve fibrosis and calcification. 
The fibrocalcific volume (sum of indexed non- calcific and 
calcific volumes) was compared with aortic valve peak 
velocity and, in a subgroup, histology and valve weight.
Results Contrast- enhanced CT calcium volumes 
correlated with CT calcium score (r=0.80, p<0.001) 
and peak aortic jet velocity (r=0.55, p<0.001). The 
fibrocalcific ratio decreased with increasing aortic 
stenosis severity (mild: 1.29 (0.98–2.38), moderate: 0.87 
(1.48–1.72), severe: 0.47 (0.33–0.78), p<0.001) while 
the fibrocalcific volume increased (mild: 109 (75–150), 
moderate: 191 (117–253), severe: 274 (213–344) mm3/
cm2). Fibrocalcific volume correlated with ex vivo valve 
weight (r=0.72, p<0.001). Compared with the Agatston 
score, fibrocalcific volume demonstrated a better 
correlation with peak aortic jet velocity (r=0.59 and 
r=0.67, respectively), particularly in females (r=0.38 and 
r=0.72, respectively).
Conclusions Contrast- enhanced CT assessment of 
aortic valve calcific and non- calcific volumes correlates 
with aortic stenosis severity and may be preferable to 
non- contrast CT when fibrosis is a significant contributor 
to valve obstruction.
INTRODUCTION
The pathogenesis of aortic stenosis involves an 
initiation phase characterised by mechanical injury, 
lipid deposition and a localised inflammatory 
response, followed by a propagation phase where 
progressive valve fibrosis and calcification promote 
worsening valvular stenosis.1 Recent guidelines 
recommend non- contrast CT calcium scoring of 
the aortic valve (CT- AVC) as an arbiter of aortic 
stenosis severity when echocardiographic measure-
ments are discordant.2 This recommendation is 
based on data demonstrating the diagnostic accu-
racy of CT- AVC as a flow- independent measure and 
its correlation with disease progression and clinical 
events.3–5 However, CT- AVC has several important 
limitations. First, it offers little detail about valve 
morphology and is unable to localise the anatom-
ical distribution of calcium in the valve and 
surrounding structures. Second, CT- AVC cannot 
quantify fibrosis, an important contributor to valve 
stenosis, and may therefore misclassify disease 
severity, particularly in young females and those 
with bicuspid valves.6 7 Third, it demonstrates only 
moderate associations with haemodynamic severity 
on echocardiography. Fourth, different thresh-
olds for severe aortic stenosis have been proposed 
for males and females, with females consistently 
demonstrating lower calcium burden for a given 
degree of valvular stenosis, even after correction 
for body size.3–5
Contrast CT angiography is widely used to assess 
and quantify calcific and non- calcific plaques in 
the coronary vasculature.8 It is the gold standard 
method of anatomical assessment before tran-
scatheter aortic valve intervention and is routinely 
incorporated into clinical workflows.9 10 In the 
present study, we used contrast- enhanced cardiac 
CT to evaluate aortic valve calcium volumes and 
also non- calcific leaflet thickening as a marker of 
valve fibrosis. We hypothesised that this technique 
would provide insights into the pathogenesis of 




This was a post hoc analysis of patients with aortic 
stenosis (peak aortic jet velocity >2.5 m/s) from 
two study cohorts. The first cohort was the Study 
Investigating the Effect of Drugs Used to Treat 
Osteoporosis on the Progression of Aortic Stenosis 
(SALTIRE2) randomised controlled trial of novel 
drug treatments in aortic stenosis (NCT 02132026) 
which recruited individuals >50 years of age with 
aortic stenosis from the Edinburgh Heart Centre 
(online supplemental data). The second cohort 
comprised patients from the AVCa study (Quebec 
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Heart and Lung Institute) in whom contrast- enhanced CT was 
performed <3 months prior to surgical aortic valve replace-
ment (online supplemental data). A control group was selected 
from patients without aortic stenosis in the Dual Antiplatelet 
Therapy to Reduce Myocardial Injury (DIAMOND) trial (NCT 
02110303), based on the lack of visual aortic valve calcification 
on CT.
Study assessments and data collection
Clinical evaluation and echocardiography were undertaken as 
study- based procedures. CT- AVC and contrast- enhanced CT 
were performed in SALTIRE2 and DIAMOND, while contrast- 
enhanced CT scans, explanted aortic valve weights and histology 
were available in patients from AVCa.
Image analysis
Doppler echocardiography
Echocardiographic assessment was performed using a stan-
dardised protocol.11 For the purposes of this post hoc analysis, 
aortic stenosis severity was categorised using peak aortic jet 
velocity (mild: 2.6–2.9 m/s, moderate: 3.0–4.0 m/s, severe: >4.0 
m/s). Mean values were taken from three measurements when 
patients were in sinus rhythm and five measurements when in 
atrial fibrillation.
Computed tomography
Baseline CT imaging was performed on a 128- detector CT 
scanner (Biograph mCT, Siemens) using automated tube voltage 
modulation (CARE Dose 4D, 100–120 kV) or a 64- detector 
CT scanner (Somatom Definition, Siemens) with 0.75 mm slice 
thickness for contrast- enhanced CT or a tube voltage of 120 kV 
with 3 mm slice thickness for CT- AVC. ECG- gated CT- AVC and 
contrast- enhanced CT angiography were performed in diastole 
and breath held in expiration.
All CT analyses were performed blinded to echocardiographic 
assessments and vice versa. CT- AVC was quantified by an experi-
enced operator (TP) using dedicated software (Vitrea Advanced, 
Vital Images, Minnetonka, USA).5 Analysis of contrast- enhanced 
CT was performed using OsiriX (V.8.0.3, Pixmeo SARL, 
Geneva, Switzerland). ECG- gated contrast- enhanced CT images 
were reconstructed in diastole. A multiplanar reconstruction was 
oriented in the short- axis plane of the aortic valve and, using 
the annulus as the reference slice, resliced in 3 mm increments 
through the valve.12 13 Slice thickness was selected to be consis-
tent with CT- AVC. Blood pool contrast attenuation (Hounsfield 
units, HU) was sampled within a 2 cm2 circular region of interest 
in the centre of the aortic root lumen at the level of the sinotu-
bular junction.
Quantification of aortic valve calcium volume and non- calcific 
leaflet volume was then performed using SliceOmatic (Tomo-
Vision, Magog, Canada). Using reoriented en face images, the 
region- growing tool was employed to select voxels within a 
defined range of attenuation values (online supplemental figure 
1). The lower threshold for detection of calcium was 3 SDs above 
the mean attenuation measured within the blood pool region of 
interest. For non- calcific leaflet tissue, a fixed lower threshold of 
30 HU was employed to exclude artefact (eg, photon starvation 
adjacent to dense calcification). The upper threshold for non- 
calcific tissue was calibrated to blood pool attenuation according 
to analysis of a derivation cohort comprising 100 patients’ scans. 
Two independent observers titrated the upper threshold for non- 
calcific leaflet thickening starting at 200 HU and adjusting by 
increments of 25 HU in either direction until the margins of the 
three aortic valve cusps were delineated without any highlighting 
of the blood pool. When this visually determined threshold (x) 
was plotted against mean blood pool attenuation (y), a strong 
linear relationship was identified (r2=0.90, p<0.001) with the 
equation x=41.46+0.42(y). Using these thresholds, areas of 
calcium and non- calcific leaflet thickening were assessed and 
quantified. Each adjacent 3 mm slice was assessed so that the 
whole volume of the valve was covered, with care to avoid 
regions of calcification in the aorta and coronary arteries.
Indexing to aortic annulus area
Leaflet volumes were indexed to the annulus area measured on 
contrast- enhanced CT. This method is widely used and repeat-
able.9 14 Valve weights were also indexed to the annulus area.
Fibrocalcific ratio and fibrocalcific volume
The fibrocalcific ratio was derived by dividing the non- calcific 
by the calcific indexed leaflet volumes. A ratio >1.0 indicated 
a predominance of non- calcific (fibrotic) volume in the valve, 
while a ratio ≤1.0 indicated that ≥50% of the measured volume 
comprised calcification. The fibrocalcific volume was calculated 
by adding the indexed calcific and non- calcific leaflet volumes.
Valve histology
In the AVCa cohort, aortic valves were excised at surgery, placed 
in a container filled with 4-(2- hydroxyethyl)-1- piperazineet
hanesulfonic acid (HEPES) solution and examined by a single 
pathologist who was blinded to the CT and echocardiographic 
assessments. One of the cusps was decalcified in Cal- Ex (Fisher, 
Nepean, Ontario, Canada) for 24 hours and fixed in formalde-
hyde 10% for histological processing. Aortic valve leaflets were 
embedded in optimal cutting temperature compound and 6 μm 
sections were obtained from a skilled operator using a cryotome. 
At least five histological sections per leaflet were analysed with 
Masson’s trichrome or Verhoeff- van Gieson staining to assess 
regions of fibrosis, calcification, thrombus or lipid. Semiquan-
titative assessment of valve fibrosis (1: mild, 2: moderate, 3: 
severe) and calcification (Warren- Yong score—1: absent, 2: mild 
valve thickening and early nodular calcification, 3: moderate 
thickening with many calcified nodules, 4: severe thickening 
with many calcified nodules) was performed according to previ-
ously published techniques.7 15 16 Valve cusps and any accom-
panying fragments were removed from HEPES solution, placed 
on absorbing paper and then weighed on laboratory scales with 
a tolerance of 0.01 g. Areas of non- calcific leaflet thickening 
observed on the CT were targeted for histological analysis.
Statistical analysis
Baseline characteristics are reported as number (percentages) for 
categorical variables and mean±SD or median (IQR) for contin-
uous variables as appropriate. Continuous variables were tested 
for normality with the Shapiro- Wilk test. One- way analysis of 
variance was used to compare continuous data across multiple 
variables. The χ2 test was used to compare categorical variables 
while the Student’s t- test or Wilcoxon rank sum test was used 
to compare continuous outcomes between two independent 
groups depending on whether they were normally distributed. 
Spearman's rank correlation coefficient was performed to assess 
the relationship between CT and echocardiographic measures. 
Linear regression models were constructed with peak aortic 
jet velocity as the dependent variable and age, female sex and 
either Agatston score or indexed fibrocalcific volume (both log2 
transformed) as the dependent variables, with female sex and 
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each of the latter as interaction terms. Interobserver variability 
was tested using the intraclass correlation coefficient (ICC; two- 
way random effects, agreement). Significance was taken at the 
two- sided 5% level (p<0.05). Statistical analysis was undertaken 
using R V.4.0.2 (Vienna, Austria).
RESULTS
A total of 164 participants with aortic stenosis (41 mild, 
89 moderate, 34 severe) were included in the main analysis 
(table 1). The median age was 71 (66–77) years and the majority 
were male (78%). All patients had a left ventricular ejection 
fraction ≥50%. Peak aortic jet velocity was slightly higher in 
men (table 2), although this was not statistically significant. Four 
of 36 females were classified as severe aortic stenosis (11%) 
compared with 30 of 128 males (23%). Other baseline charac-
teristics were similar between females and males. The time from 
echocardiography to CT was 0 (0–9) days. Thirty- eight partici-
pants (50% female, 67 (60–73) years) without evidence of aortic 
stenosis comprised the control group.
Aortic valve calcification
In the control group, no aortic valve calcification was observed 
on either non- contrast or contrast- enhanced CT. In the aortic 
stenosis cohort, the indexed contrast CT calcium volume 
increased with stenosis severity (mild: 39 (19–64), moderate: 
85 (46–187), severe: 190 (113–254) mm3/cm2; figure 1A) and 
correlated moderately well with peak aortic jet velocity (r=0.62, 
p<0.001; online supplemental table 1). There was excellent 
interobserver reproducibility (ICC: 0.95; 95% CI 0.88 to 0.98, 
p<0.001; online supplemental figure 2). Females had lower 
Agatston scores as well as indexed contrast CT calcium volumes 
compared with males (table 2).
Non-calcific leaflet volume
In the control cohort, the indexed non- calcific leaflet volume 
was 30 (20–43) mm3/cm2 with no sex differences (females: 33 
(19–43) vs males: 27 (21–39) mm3/cm2, p=0.18). In patients 
with aortic stenosis, indexed non- calcific leaflet volumes were 
higher than in the control cohort but only trended towards an 
increase with more severe stenosis (mild: 57 (40–88), moderate: 
81 (54–109), severe: 85 (61–127) mm3/cm2; figure 2B). There 
was a weak correlation with peak velocity (r=0.27, p<0.001, 
online supplemental table 1). Interobserver reproducibility was 
excellent (ICC: 1.00; 95% CI 0.99 to 1.00, p<0.001; online 
supplemental figure 2). In contrast to the indexed calcific 
volume, the indexed non- calcific volume was only slightly lower 
in females than males (table 2).
Fibrocalcific volume and fibrocalcific ratio
The indexed fibrocalcific volume increased across aortic stenosis 
severity categories (mild: 109 (69–148), moderate: 196 (125–
261), severe: 279 (217–412) mm3/cm2; figure 1C). Compared 
with the Agatston score, fibrocalcific volume demonstrated 
a better correlation with peak aortic jet velocity (r=0.59 and 
r=0.67, respectively), particularly in females (r=0.38 and 
r=0.72, respectively) (table 3, figure 2A,B). The fibrocalcific 
ratio decreased with increasing stenosis severity (mild: 1.29 
(0.90–2.30), moderate: 0.83 (0.47–1.57), severe: 0.52 (0.34–
0.94)) and was higher in females than in males (online supple-
mental figure 3).
On multivariable linear regression modelling with peak aortic 
jet velocity as the dependent variable and age, sex and Agatston 
score as independent variables, the latter two covariates were 
independently associated with peak velocity (p=0.001 and 
p<0.001, model adjusted r2=0.31), with an interaction between 
female sex and Agatston score (p=0.002; online supplemental 
table 2). When constructing the same model but replacing Agat-
ston score with indexed fibrocalcific volume, the only inde-
pendent predictor of peak aortic jet velocity was the indexed 
fibrocalcific volume (p<0.001, model adjusted r2=0.36). There 







Age 71 (66–77) 71 (66–77) 71 (66–77) 0.820
Hypertension 116 (70.7) 25 (69.4) 91 (71.1) 0.999
Hypercholesterolaemia 95 (57.9) 22 (61.1) 73 (57.0) 0.752
Diabetes mellitus 43 (26.2) 8 (22.2) 35 (27.3) 0.705
Coronary artery disease 62 (37.8) 15 (41.7) 47 (36.7) 0.696
Current/ex- smoker 65 (39.6) 12 (33.3) 53 (41.4) 0.512
Medications
  Antiplatelets 92 (56.1) 16 (44.4) 76 (59.4) 0.146
  Oral anticoagulation 17 (10.4) 3 (8.3) 14 (10.9) 0.153
  ACE inhibitor/ARB 82 (50.0) 17 (47.2) 65 (50.8) 0.850
  Beta blocker 61 (37.2) 11 (30.6) 50 (39.1) 0.462
  Statin 107 (65.2) 19 (52.8) 88 (68.8) 0.092
ARB, angiotensin receptor blocker.








  Peak aortic jet velocity (m/s) 3.44 (3.00–3.87) 3.26 (2.96–3.61) 3.53 (3.00–3.94) 0.106
  Mean aortic valve gradient (mm Hg) 27 (18–34) 24 (18–32) 28 (19–34) 0.400
  Aortic valve area (cm2) 1.01 (0.82–1.24) 1.03 (0.84–1.18) 1.01 (0.81–1.27) 0.735
CT
  Bicuspid aortic valve 11 (7) 0 (0) 11 (9) 0.120
  Agatston score 1163 (670–2169) 460 (206–1010) 1474 (823–2362) <0.001
  Indexed contrast CT calcific volume (mm3/cm2) 82 (42–181) 33 (17–75) 103 (55–194) <0.001
  Indexed contrast non- calcific volume (mm3/cm2) 79 (49–104) 57 (39–98) 82 (56–104) 0.089
  Indexed fibrocalcific volume (mm3/cm2) 187 (115–265) 115 (72–184) 203 (130–279) <0.001
  Fibrocalcific ratio 0.86 (0.47–1.54) 1.27 (0.78–4.23) 0.76 (0.41–1.45) 0.002
  Blood pool radiodensity (HU) 401 (326–511) 550 (453–600) 366 (319–467) <0.001
HU, Hounsfield units.
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was no interaction with female sex or difference in model fit on 
one- way analysis of variance (p=0.27).
Histology
Valve weight was available in 26 patients. There was a strong 
correlation between indexed fibrocalcific volume and indexed 
valve weight (figure 3A), in contrast to a probable weak correla-
tion between peak aortic jet velocity and indexed valve weight 
(r=0.37, p=0.06). Histological examination confirmed the 
presence of valve fibrosis that spatially correlated with areas of 
non- calcific leaflet thickening on CT (figure 4). There was no 
thrombus or gross lipid deposition observed in these areas. The 
indexed fibrocalcific volume was higher in patients with higher 
Warren- Yong and fibrosis scores (figure 3B,C, online supple-
mental figure 4).
DISCUSSION
We describe a novel method of contrast- enhanced CT analysis 
that allows assessment of both aortic valve calcification and 
non- calcific leaflet thickening (fibrosis) in patients with aortic 
stenosis. We demonstrate the feasibility of contrast- enhanced 
CT assessment of aortic stenosis severity, with the indexed fibro-
calcific volume correlating better with peak aortic jet velocity 
than CT- AVC in this cohort, particularly in females. Quanti-
fying valve fibrosis, a facet of valvular disease that cannot be 
assessed with non- contrast CT, may be therefore important in 
some patients. Given the routine use of contrast- enhanced CT 
in clinical workflows for transcatheter aortic valve implantation, 
fibrocalcific volumes could be readily integrated into clinical 
practice, providing an alternative assessment for patients with 
uncertain disease severity.
Discordant echocardiographic measures of aortic stenosis 
severity are observed in around one- third of patients.3 17 CT- AVC 
has emerged as a useful tool in these patients, providing an 
anatomical, flow- independent assessment of disease severity that 
is well validated in concordant disease and supported by inter-
national guidelines. We found that assessments of valve calcifi-
cation on contrast- enhanced CT correlated well with CT- AVC. 
However, progressive valve stiffening and narrowing in aortic 
stenosis occurs due to both fibrosis and calcification,18 19 and 
CT- AVC, which quantifies only the latter, may underestimate 
aortic stenosis severity in cases where valve obstruction is 
predominantly due to the former. Sex- specific CT- AVC thresh-
olds for severe aortic stenosis may indirectly adjust for the 
increased valve fibrosis observed in females and generally offer 
good diagnostic accuracy compared with echocardiography.5 
Figure 1 Indexed contrast CT leaflet volumes and aortic stenosis severity. Box plots of indexed contrast CT calcific (A), non- calcific (B), and 
fibrocalcific (C) volumes according to aortic stenosis severity. P values for Wilcoxon rank sum test.
Figure 2 Fibrocalcific volume and standard measures of aortic stenosis severity. Scatter plots of indexed fibrocalcific volume, Agatston score (A) and 
peak aortic jet velocity (B). R and p values for Spearman's rank correlation coefficient.
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However, patients with severe aortic stenosis and concordant 
haemodynamic assessments of valve disease severity can have 
low Agatston scores.6 In addition, it can be challenging to differ-
entiate valvular calcification from calcification of the aorta, left 
ventricular outflow tract, mitral valve or coronary arteries on 
axial non- contrast CT images. As such, there is a clear ratio-
nale for exploring alternative anatomical assessments of aortic 
stenosis that can overcome these issues.
We found the fibrocalcific volume to be a good measure of 
aortic stenosis severity that correlated well with echocardio-
graphic measurements of valve haemodynamics and compared 
favourably with CT- AVC. Contrast- enhanced CT leaflet volumes 
also correlated with valve weight and semiquantitative histolog-
ical assessments of calcification and fibrosis, although these find-
ings are limited by our small sample size. Given the superior 
anatomical detail afforded by contrast- enhanced CT, calcific and 
non- calcific volumes also had excellent reproducibility.
The fibrocalcific ratio, a reflection of the relative contribu-
tions of non- calcific and calcific tissue to leaflet thickening, 
is highly variable. As an isolated measure, it is not necessarily 
useful in mildly or non- diseased aortic valves, where the ratio 
is infinite when calcium is absent. However, in our study, it is 
notable that although females—who comprised a minority of 
the cohort—had only slightly lower peak aortic jet velocities, 
their Agatston scores and indexed contrast CT calcific volumes 
were much lower than in males. Consequently, the fibrocalcific 
ratio was higher in females. It would therefore be congruent 
that the Agatston score correlated less well with peak aortic jet 
velocity in females. This finding is out of keeping with the larger 
evidence base, where the validation of CT- AVC was undertaken 
in populations with more severe disease.5 This is further empha-
sised by multivariable regression models in our cohort, which 
demonstrated that although Agatston score was independently 
associated with peak aortic jet velocity after adjusting for age 
and sex, there was an interaction between sex and Agatston 
score. Overall, we would suggest our findings do concur with 
existing data that demonstrate similar degrees of valve obstruc-
tion in females with lower valve calcium load, even indexed for 
body size. The poor performance of the Agatston score likely 
reflects the small sample size of females enrolled in this study, 
most of whom had non- severe aortic stenosis.
Our study has several strengths. It comprised patients prospec-
tively recruited into studies across the spectrum of aortic stenosis 
severity, with systematic multimodality imaging assessments 
undertaken. The novel image analysis protocol proposes the use 
of flexible thresholds for defining calcific and non- calcific valve 
thickening based on contrast attenuation in the blood pool, and 
defines the aortic valve plane and annulus sizing in a uniform 
fashion that is well established. As a consequence, our technique 
is very reproducible. However, there are also some important 
limitations. The formula to set HU thresholds is derived, and as 
such will inevitably underestimate or overestimate non- calcific 
or calcific volumes in tissues that approach these thresholds, or 
where there is substantial variation in blood pool opacification. 
Accurate image analysis also requires adequate image quality 
and contrast opacification, and is challenging at the upper and 
lower extremes of blood pool contrast load. The majority of 
the cohort comprised patients with non- severe aortic stenosis, 
which differs from the derivation and validation cohorts for 
CT- AVC. A minority of the cohort were female and as such the 
sex differences observed must be interpreted with caution. Simi-
larly, the number of patients with bicuspid valves—an important 
subgroup that differs from ‘degenerative’ aortic stenosis—was 
too limited to examine. We did not study patients with a low- 
flow state, which is a particular cohort where there is often 
diagnostic uncertainty. Consequently, the generalisability of this 
initial report is limited, and requires further validation in a larger 
cohort that comprised more females and more patients with 
severe aortic stenosis. Finally, our image analysis method is rela-
tively time consuming, involving multiple steps and transfer of 
data between different software packages (~45 min per case). An 
integrated software solution to facilitate more rapid image anal-
ysis while maintaining accuracy and reproducibility is currently 
being investigated.
Table 3 Correlations between CT aortic valve assessments and 
echocardiography
Peak aortic jet 
velocity P value*
Agatston score†
  All 0.59 <0.001
  Male 0.57 <0.001
  Female 0.38 0.054
Indexed contrast CT fibrocalcific volume
  All 0.67 <0.001
  Male 0.66 <0.001
  Female 0.72 <0.001
*Spearman’s rank correlation coefficients.
†n=135/164.
Figure 3 (A) Scatter plot of indexed valve weight and indexed fibrocalcific volume. (B) Box plots of indexed fibrocalcific volume and Warren- Yong 
score. (C) Box plots of indexed fibrocalcific volume and fibrosis score. P values for Spearman's rank correlation coefficient (A) and Wilcoxon rank sum 
test (B, C).
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In conclusion, the aortic valve fibrocalcific volume as assessed 
by contrast- enhanced CT is an accurate and reproducible 
measure of aortic stenosis severity that quantifies both calcific 
and non- calcific leaflet volumes. As a promising tool for the 
assessment of aortic stenosis, the next steps are to improve effi-
ciencies in image analysis, followed by larger scale validation to 
determine clinically useful thresholds.
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Figure 4 Contrast- enhanced CT and histology. Case 1: A tricuspid aortic valve from a woman with a large amount of fibrosis (red) compared with 
calcification (green) on CT. Histology confirms a preponderance of fibrosis in the valve consistent with the CT findings. There was no clear evidence of 
valve thrombosis or lipid infiltration. Red arrow denotes the leaflet corresponding to histology. Time from CT to surgery: 15 days. Masson’s trichrome 
staining: blue sections represent collagen; red/purple represents calcium. Case 2: A tricuspid aortic valve from a man with a small amount of fibrosis 
compared with calcification (from the three CT slices containing the aortic valve this one was the only one with significant fibrosis). This was again 
confirmed on histological analysis of the valve leaflet. Red arrow denotes the leaflet corresponding to histology. Time from CT to surgery: 15 days. 
Verhoeff- van Gieson staining: black represents elastic fibres, pink collagen fibres and yellow calcium. Case 3: A bicuspid aortic valve from a man 
with extensive fibrosis and calcification in the valve. Findings were again confirmed on histology with the spatial distribution of calcium and fibrosis 
on histology appearing similar to the calcific and non- calcific leaflet thickening on CT (Verhoeff- van Gieson staining). Red arrow denotes the leaflet 
corresponding to histology. Time from CT to surgery: 21 days.
Key messages
What is already known on this subject?
 ► Aortic valve calcium scoring using non- contrast CT is a 
measure of aortic stenosis severity that has been validated 
against echocardiography and is recommended as an arbiter 
of disease severity when echocardiography is equivocal. 
However, it provides poor anatomical definition and cannot 
assess non- calcific leaflet thickening, which may contribute to 
valvular obstruction.
What might this study add?
 ► We demonstrate the feasibility of using contrast- enhanced CT 
to quantify calcific and non- calcific valve leaflet thickening. 
Both the calcific leaflet volume and combined fibrocalcific 
leaflet volume correlated well with echocardiography, similar 
to non- contrast aortic valve calcium scoring. The addition of 
the non- calcific leaflet volume to the calcific leaflet volume 
particularly improved the correlation with echocardiography 
in females.
How might this impact on clinical practice?
 ► Our early data require wider validation, but there are clear 
potential clinical applications. The need for dedicated non- 
contrast CT as a measure of aortic stenosis severity may 
be obviated in patients already undergoing contrast CT—a 
standard assessment in the patients being considered for 
transcatheter aortic valve implantation, in whom a proportion 
may have discordant echocardiographic findings. Contrast- 
enhanced CT may also provide a more accurate anatomical 
assessment of stenosis severity in patients where leaflet 
fibrosis, rather than calcification, is a major contributor to 
valve obstruction.
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